Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Patients ‘sceptical’ about biosimilars, says EULAR

Concerns for safety of drugs for arthritis and other musculoskeletal diseases

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

AZ escapes censure over cancer tweet

Firm did not breach UK’s Code of Practice over survival statistics post

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

Flurry of FDA guidance firms up biosimilar policy

The American regulator has released new biosimilar Q&A document

Roche Basel Switzerland

Roche moves closer to US filing for alectinib

Results showed alectinib able to shrink tumours in half of cases

- PMLiVE

Cancer drug spend tops $100bn in 2014

But payers are starting to bulk at increasing prices

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links